Magic™ Human OX40L (TNFSF4) Stable Cell Line

Product Information

Target Family

Oncology

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;HFL1

Target Classification

Oncology Cell Lines

Target Research Area

Cardiovascular Research

Related Diseases

Myocardial Infarction; Systemic Lupus Erythematosus

Gene ID

Human:7292

UniProt ID

Human:P23510

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The application of TNFSF4 (tumor necrosis factor superfamily member 4) has been studied in various fields. In medicine, TNFSF4 has been investigated as a potential prognostic biomarker in hepatocellular carcinoma (HCC). The gene DHRS1, a member of the short-chain dehydrogenase/reductase superfamily, has been identified as a predictor of HCC. DHRS1-associated immunomodulators have been found to strongly correlate with survival in HCC patients. A risk score based on these immunomodulators has been developed and shown to be an independent indicator of HCC prognosis. TNFSF4 has also been implicated in osteosarcoma, where it influences the prognostic and immune microenvironment of the disease. Ferroptosis-related long non-coding RNAs (FRLncs) associated with TNFSF4 have been identified as potential prognostic markers in osteosarcoma. In addition, TNFSF4 has been found to be activated in sclerotic-type cutaneous chronic graft-versus-host disease, a complication of allogeneic hematopoietic stem cell transplantation. The disease exhibits strong T helper 1 (Th1) skewing and upregulation of TNFSF4 and other related cytokines. Furthermore, TNFSF4 has been studied in breast cancer, where it is associated with ferroptosis-related genes. A prognostic model based on these genes has been developed, and TNFSF4 has been identified as a potential therapeutic target. Overall, TNFSF4 has shown promise as a prognostic biomarker and therapeutic target in various diseases.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for Magic™ Human OX40L (TNFSF4) Stable Cell Line (S01YF-1023-PY242). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Smith (Verified Customer)

What is the significance of TNFSF4 in cancer immunotherapy? Sep 13 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFSF4, known as OX40L, plays a crucial role in enhancing immune responses against tumors and is being explored as a target for cancer immunotherapy. Sep 13 2020

chat Cameron Jones (Verified Customer)

How does TNFSF4 polymorphism affect disease susceptibility? Mar 13 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

Polymorphisms in TNFSF4 have been associated with increased susceptibility to diseases like breast cancer and systemic lupus erythematosus, highlighting its genetic influence on disease risk. Mar 13 2021

Published Data

Fig.1 Significant inhibition of the expression of BCL-XL, the critical factor responsible for the suppression of tumor cell apoptosis, can be achieved through the blocking of TNFSF4/TNFRSF4 signaling.

Subcutaneous co-implantation of lung adenocarcinoma cells (A549 or SPC-A1, with or without TNFRSF4 knockdown) with fibroblasts (HFL-1) that overexpress TNFSF4 was performed in nude mice. The expression of BCL-XL in A549 or SPC-A1 cells was significantly inhibited by TNFRSF4 knockdown. The observed outcomes indicated notable differences, with **p < 0.01, while NC (negative control) and ns (no significance) were also included in the analysis.

Ref: Li, Yan, et al. "Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells." Cancer Letters 497 (2021): 212-220.

Pubmed: 33132120

DOI: 10.1016/j.canlet.2020.10.032

Research Highlights

Xu, Sa. et al. "Construction and validation of a immune-related prognostic gene DHRS1 in hepatocellular carcinoma based on bioinformatic analysis." Medicine, 2023.
A member of the short-chain dehydrogenase/reductase superfamily (DHRS1, SDR19C1) has been identified as a potential predictor of hepatocellular carcinoma (HCC). However, the specific role of DHRS1 in HCC immunity remains unclear. A systematic analysis was conducted using transcriptional and clinical data from the Tumor Immune Estimation Resource and cBioPortal databases to investigate the association between DHRS1 and HCC immunity. Through univariate and multivariate Cox analyses, six DHRS1-associated immunomodulators were found to strongly correlate with survival. These findings were validated using an external validation set and a risk score was created to classify patients into high and low risk categories. Further analyses showed a correlation between DHRS1 gene copy numbers or mRNA levels and immune cell infiltration in HCC. A signature based on these six DHRS1-related immunomodulators was generated and it was found to be an independent indicator of HCC prognosis, with a high predictive accuracy. External validation sets further confirmed the validity of this risk score. In addition, a prognostic nomogram and calibration curve were constructed to predict HCC outcomes. The results suggest that the DHRS1 gene may play a role in regulating HCC immunity and the identified immune signature could be a promising prognostic biomarker for HCC.
Xu, Sa. et al. "Construction and validation of a immune-related prognostic gene DHRS1 in hepatocellular carcinoma based on bioinformatic analysis." Medicine, 2023.
Pubmed: 37861541 DOI: 10.1097/MD.0000000000035268

Yang, Mingyi. et al. "Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment." Journal of orthopaedic surgery and research, 2023.
This study aims to explore the role of ferroptosis-related long non-coding RNAs (FRLncs) in the prognosis and immune microenvironment of osteosarcoma (OS). A foundational framework will be established to aid in making clinical decisions for OS management.
Yang, Mingyi. et al. "Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment." Journal of orthopaedic surgery and research, 2023.
Pubmed: 37858131 DOI: 10.1186/s13018-023-04286-3